Phaseline

Companies › Corxel Pharmaceuticals

Corxel Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CX11–Phase 2Type II Diabetes Mellitus; Obesity & OverweightMar 2027
JX10
Thrombolytic agent
–Phase 2Acute Ischemic StrokeOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07652047CX11Phase 1Obesity & OverweightMetabolic and endocrineMar 2027
NCT07340320CX11Phase 2Type II Diabetes MellitusMetabolic and endocrineApr 2027
NCT06990867JX10Phase 2Acute Ischemic StrokeNeurologyOct 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shenzhen Wingor Biotechnology NeuroBiogen Urovant Sciences MediciNova PRG Science & Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.